Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?1

Eitemau Tebyg

• Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9[S]
  gan: Sam J.L. van der Tuin, et al.
  Cyhoeddwyd: (2015-11-01)
• Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S]
  gan: Michael Davidson, et al.
  Cyhoeddwyd: (2013-02-01)
• Anacetrapib as a potential cardioprotective strategy
  gan: Di Bartolo BA, et al.
  Cyhoeddwyd: (2017-12-01)
• The metabolism and anti-atherogenic properties of HDL
  gan: Kerry-Anne Rye, et al.
  Cyhoeddwyd: (2009-01-01)
• Effects of anacetrapib in patients with atherosclerotic vascular disease
  gan: Bowman, L, et al.
  Cyhoeddwyd: (2017)